Skaland I, Øvestad I, Janssen E A M, Klos J, Kjellevold K H, Helliesen T, Baak J P A
Department of Pathology, Stavanger University Hospital, Stavanger, Norway.
J Clin Pathol. 2008 Jan;61(1):68-71. doi: 10.1136/jcp.2007.046763. Epub 2007 Apr 5.
HER2/neu expression and fluorescence in situ hybridisation (FISH) amplification have therapeutic significance.
To compare subjective HER2/neu expression scores with digital image analysis (DIA) and conventional and modified FISH scores in breast cancer.
Sixty HercepTest-immunostained breast carcinomas, prospectively scored as consensus 2+ and 3+ (DAKO protocol) by two observers, were analysed with DIA, and conventional (Vysis) and modified FISH scoring protocols.
With consensus scoring, 23 (38%) of the 60 cases were 2+ and 37 (62%) were 3+. Agreement with DIA scores was 100%. With conventional FISH scoring, 4 of the 3+ cases did not show amplification, but all of those negative cases had high HER2/neu copy numbers. With the modified FISH scoring protocol, all HercepTest immunohistochemical 3+ cases were amplified. Of the 2+ cases, 3 were amplified with the modified FISH protocol and 4 with the conventional FISH protocol.
Modified FISH scores were better correlated with HercepTest 3+ consensus and DIA scores than were conventional FISH scores. HER2/neu DIA scoring is a cost-effective supplementary tool in surgical pathology.
HER2/neu表达及荧光原位杂交(FISH)扩增具有治疗意义。
比较乳腺癌中HER2/neu主观表达评分与数字图像分析(DIA)以及传统和改良FISH评分。
对60例经赫赛汀检测免疫染色的乳腺癌进行分析,由两名观察者按照DAKO方案前瞻性地评定为一致性2+和3+,采用DIA、传统(Vysis)和改良FISH评分方案。
采用一致性评分,60例病例中23例(38%)为2+,37例(62%)为3+。与DIA评分的一致性为100%。采用传统FISH评分时,3+病例中有4例未显示扩增,但所有这些阴性病例的HER2/neu拷贝数均较高。采用改良FISH评分方案时,所有赫赛汀检测免疫组化3+病例均有扩增。在2+病例中,改良FISH方案有3例扩增,传统FISH方案有4例扩增。
与传统FISH评分相比,改良FISH评分与赫赛汀检测3+一致性评分和DIA评分的相关性更好。HER2/neu DIA评分是外科病理学中一种具有成本效益的辅助工具。